Aitor Ballaz Quincoces-rekin lankidetzan egindako argitalpenak (55)

2024

  1. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 143-152

  2. Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis

    Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537

  3. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  4. High-Sensitivity vs Conventional Troponin Cutoffs for Risk Stratification in Patients with Acute Pulmonary Embolism

    JAMA Cardiology, Vol. 9, Núm. 1, pp. 64-70

  5. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  6. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

    eClinicalMedicine, Vol. 73

  7. The prognostic value of blood cellular indices in pulmonary embolism

    American Journal of Hematology, Vol. 99, Núm. 9, pp. 1704-1711

2023

  1. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

    Thrombosis Update, Vol. 13

  2. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

    Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 7

  3. Feasibility of a screening algorithm for chronic thromboembolic pulmonary hypertension: The OSIRIS study

    Thrombosis Research, Vol. 228, pp. 1-9

  4. Identification of Low-risk Patients With Acute Symptomatic Pulmonary Embolism

    Archivos de Bronconeumologia, Vol. 59, Núm. 9, pp. 575-580

  5. Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations

    British Journal of Haematology, Vol. 201, Núm. 5, pp. 971-981

  6. The value of the CHAP model for prediction of the bleeding risk in patients with unprovoked venous thromboembolism: Findings from the RIETE registry

    Thrombosis Research

  7. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2811-2823

2022

  1. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

    Research and Practice in Thrombosis and Haemostasis, Vol. 6, Núm. 4

  2. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

    Chest, Vol. 161, Núm. 2, pp. 524-534

  3. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 725-734

  4. Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry

    Frontiers in Medicine, Vol. 9

  5. The hazard of combining anticoagulants with antiplatelets in patients with venous thromboembolism: Findings from the RIETE registry

    Thrombosis Research

2021

  1. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 8, pp. 1981-1989